Related Experiment Video
Updated: Mar 15, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance
Steven B Ouellette1, Brett M Noel1, Laurie L Parker1
1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, United States of America.
Abstract:
Kinase enzymes are an important class of drug targets, particularly in cancer. Cell-based kinase assays are needed to understand how potential kinase inhibitors act on their targets in a physiologically relevant context. Current cell-based kinase assays rely on antibody-based detection of endogenous substrates, inaccurate disease models, or indirect measurements of drug action. Here we expand on previous work from our lab to introduce a 96-well plate compatible approach for measuring cell-based kinase activity in disease-relevant human chronic myeloid leukemia cell lines using an exogenously added, multi-functional peptide substrate. Our cellular models natively express the BcrAbl oncogene and are either sensitive or have acquired resistance to well-characterized BcrAbl tyrosine kinase inhibitors. This approach measures IC50 values comparable to established methods of assessing drug potency, and its robustness indicates that it can be employed in drug discovery applications. This medium-throughput assay could bridge the gap between single target focused, high-throughput in vitro assays and lower-throughput cell-based follow-up experiments.
Insights
A new cell-based kinase assay uses a peptide substrate to measure drug potency in chronic myeloid leukemia models. This robust, medium-throughput method aids in cancer drug discovery.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Kinase enzymes are crucial drug targets, especially in cancer therapy.
- Existing cell-based kinase assays have limitations, including reliance on antibodies, inaccurate models, and indirect measurements.
- There is a need for improved methods to assess kinase inhibitor activity in relevant cellular contexts.
Purpose of the Study:
- To develop and validate a 96-well plate compatible cell-based kinase assay for measuring drug potency.
- To utilize disease-relevant chronic myeloid leukemia (CML) cell lines expressing the BcrAbl oncogene.
- To assess the activity of BcrAbl tyrosine kinase inhibitors in both sensitive and resistant CML models.
Main Methods:
- Developed an assay using an exogenously added, multi-functional peptide substrate.
- Employed CML cell lines that natively express the BcrAbl oncogene.
- Measured IC50 values to determine drug potency.
Main Results:
- The assay demonstrated robustness and comparability to established methods for assessing drug potency.
- Achieved IC50 values comparable to existing techniques.
- The assay is suitable for drug discovery applications.
Conclusions:
- The developed cell-based kinase assay provides a reliable method for measuring kinase activity in disease-relevant models.
- This medium-throughput assay can bridge the gap between in vitro and lower-throughput cell-based experiments.
- The assay is a valuable tool for cancer drug discovery, particularly for kinase inhibitors.
